Overview

Improving Driving in Young People With Autism Spectrum Disorders

Status:
Completed
Trial end date:
2019-12-16
Target enrollment:
Participant gender:
Summary
This study will examine the effects of treatment with the anti-anxiety medicine buspirone on driving performance (eye tracking) in individuals with high-functioning autism spectrum disorder (HF-ASD). The study consists of an Assessment Visit at Massachusetts General Hospital (MGH), as well as two Driving Simulation visits that will take place at Massachusetts Institute of Technology (MIT). Subjects will be given buspirone and asked to take the medication for the two days preceding the Driving Simulation Visit.
Phase:
Phase 4
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborator:
Massachusetts Institute of Technology
Treatments:
Buspirone